Monday, 16 July 2018 - 13:44
  • it
  • de
  • en
  • fr

Celgene

Celgene admits mistake

The Financial Times has published today an article reporting that US biotech Celgene has admitted it submitted at the beginning of the year an inadequate application to FDA for multiple sclerosis treatment Ozanimod. This resulted in the US authority refusing…

Recent progress in immunology

The scientific journal Science published in its latest issue a long article about the biotech Lycera, established by the researcher Gary Glick and focusing on the development of treatments for autoimmune diseases, such as psoriasis and Crohn’s disease. Additionally, the…

Celgene signs $150m agreement with Prothena to develop Alzheimer’s drug

Celgene has entered into an agreement with biotech Prothena in order to acquire the rights to three Alzheimer’s drug candidates based on three proteins identified by Prothena. Specifically, under the agreement, the companies will co-develop the drug candidates. Should these…

Celgene signs $101m cooperation agreement with Vividion Therapeutics

Vividion Therapeutics has announced today, before trading opened, that it has signed a cooperation agreement with biotech company Celgene. The agreement is aimed at developing novel therapies based on molecules modulating the levels of proteins playing a role in inflammation…

Why big pharma companies always create new spinoffs

The recent acquisitions in the pharma sector (Sanofi, Celgene, Biogen) have confirmed that the strategy adopted by many groups–i.e. spinning off part of their assets and divesting them–is the best way to grant shareholders a rich financial return. The most…

Celgene acquires Juno Therapeutics for $9bn

As everyone expected, Celgene has acquired biotech company Juno Therapeutics for $9bn, that is $87 per share, or a 91% premium over the share price before it was announced that Celgene was targeting Juno (January 16th). The deal gives Celgene…

Analysts don’t approve of Celgene’s takeover to Juno Therapeutics

Analysts are assessing Celgene’s potential takeover to Juno. Despite their different views, all experts agree that the acquisition will be very expensive ($8-$10bn) and will not provide any short-term solution to Juno’s issues. Juno Therapeutics offers Celgene the opportunity to…

Celgene about to acquire Juno Therapeutics ($5.5bn)

Celgene’s M&A season seems to never end. Few days after acquiring Impact Biomedicines for $1.1bn in cash, the US-based biotech company headquartered in New Jersey is in advanced talks to acquire Juno Therapeutics, worth at least $5.5bn. By acquiring Juno,…

Nimbus signs cooperation agreement with Celgene

US-based Nimbus Therapeutics (Cambridge MA-US) has signed a new, strategic cooperation agreement with a drug-making multinational. This time the new partner is Celgene and the alliance covers two programs in pre-clinical stage, focused on a Tyk2 inhibitor and STING non-nucleotide…